Supernus director Gemayel’s 27,277 shares convert
The merger converted his outstanding equity awards into replacement awards, with option exercise prices adjusted by the exchange ratio.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Supernus Pharmaceuticals, Inc. director Georges Gemayel reported disposing of 27,277 common shares on November 2, 2026, under the merger. Each outstanding share was cancelled and converted into the right to receive 1.5401 shares of Supernus, Inc. common stock; he received no cash consideration other than cash in lieu of a fractional share. His outstanding restricted stock units and options were assumed by Indivior, renamed Supernus, Inc., and converted into corresponding awards. The converted options’ per-share exercise prices were divided by the exchange ratio and rounded up to the nearest whole cent.
Insider Trade Summary
Other: 107,677 shares
Other
12 txns
Insider
GEMAYEL GEORGES
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Restricted Stock Unit F2, F3, F4 | 2,989 | $0.00 | $0.00 |
| Other | Director Stock Option (Right to Buy) F3 | 6,036 | $0.00 | $0.00 |
| Other | Director Stock Option (Right to Buy) F3 | 8,613 | $0.00 | $0.00 |
| Other | Director Stock Option (Right to Buy) F3 | 12,427 | $0.00 | $0.00 |
| Other | Director Stock Option (Right to Buy) F3 | 9,305 | $0.00 | $0.00 |
| Other | Director Stock Option (Right to Buy) F3 | 7,365 | $0.00 | $0.00 |
| Other | Director Stock Option (Right to Buy) F3 | 6,847 | $0.00 | $0.00 |
| Other | Director Stock Option (Right to Buy) F3, F5 | 6,293 | $0.00 | $0.00 |
| Other | Director Stock Option (Right to Buy) F3, F6 | 8,252 | $0.00 | $0.00 |
| Other | Director Stock Option (Right to Buy) F3, F7 | 7,296 | $0.00 | $0.00 |
| Other | Director Stock Option (Right to Buy) F3, F8 | 4,977 | $0.00 | $0.00 |
| Other | Common Stock F1 | 27,277 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Unit — 0 contracts (Direct);
Director Stock Option (Right to Buy) — 0 contracts (Direct);
Common Stock — 0 shares (Direct)
Holdings Before and After:
Restricted Stock Unit, 2,989 to 0 contracts (Direct);
Director Stock Option (Right to Buy), 77,411 to 0 contracts (Direct);
Common Stock, 27,277 to 0 shares (Direct)
Footnotes (8)
- F1. Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/26, Artemis Merger Sub Inc. merged with and into Supernus Pharmaceuticals, with Supernus Pharmaceuticals surviving as a wholly-owned subsidiary of Indivior. At the effective time, each outstanding share of Supernus Pharmaceuticals common stock was cancelled and automatically converted into the right to receive 1.5401 shares of Indivior common stock. In connection with the merger, Indivior changed its name to "Supernus, Inc." The reporting person's shares of Supernus Pharmaceuticals common stock were disposed of, and the shares of Supernus, Inc. common stock received in exchange were acquired, pursuant to the merger. The reporting person received no cash consideration other than cash in lieu of a fractional share.
- F2. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- F3. Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F4. These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027.
- F5. The option vests on February 23, 2024.
- F6. The option vests on February 22, 2025.
- F7. The option vests on February 19, 2026.
- F8. Each option vests on February 18, 2027.
Key Figures
Common shares disposed: 27,277 shares
Merger exchange ratio: 1.5401 shares of Supernus, Inc. common stock per Supernus Pharmaceuticals share
Restricted stock units: 2,989 units
+2 more
5 metrics
Common shares disposed
27,277 shares
Supernus Pharmaceuticals common stock; November 2, 2026
Merger exchange ratio
1.5401 shares of Supernus, Inc. common stock per Supernus Pharmaceuticals share
At the effective time of the merger
Restricted stock units
2,989 units
Scheduled to vest February 18, 2027
Director stock options
6,036 options; $38.60 exercise price per share
Expiration June 13, 2027
Director stock options
8,613 options; $39.40 exercise price per share
Expiration February 23, 2028
Key Terms
exchange ratio, restricted stock unit, cash in lieu of a fractional share, assumed
4 terms
exchange ratio financial
"multiplied by the 1.5401 exchange ratio"
The exchange ratio is the number used to decide how many shares of one company you get for each share you own in another company during a merger or acquisition. It’s like a recipe that tells you how to swap shares fairly, ensuring both companies’ values are balanced. This ratio matters because it determines how ownership divides between the companies' shareholders.
restricted stock unit financial
"Each restricted stock unit represents the right to receive one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
assumed financial
"each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What happened to Georges Gemayel's SUPN stock options and restricted stock units?
The outstanding awards were assumed by Indivior, renamed Supernus, Inc., and converted into corresponding Supernus, Inc. awards. The number of shares subject to each award was multiplied by the exchange ratio and rounded down; the per-share exercise price was divided by the ratio and rounded up to the nearest whole cent. Performance stock units were converted into time-vesting restricted stock units.
AI-generated analysis. How Rhea-AI works. Not financial advice.
